Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 272
- Registration Number
- NCT05014815
- Locations
- 🇦🇺
Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
🇦🇹Universitätsklinikum Krems, Krems, Krems an der Donau, Austria
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 58
- Registration Number
- NCT05014828
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Hospital, Hefei, Anhui, China
🇨🇳Beijing Luhe Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT04996459
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
ALPPS Combined With Tislelizumab in Liver Malignancy
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT04996446
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 60
- Registration Number
- NCT04985721
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺St Vincent's Hospital, Fitzroy, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT04981665
- Locations
- 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 70
- Registration Number
- NCT04974047
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 176
- Registration Number
- NCT04973306
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, China
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT04954781
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 126
- Registration Number
- NCT04952597
- Locations
- 🇨🇳
Mianyang Central Hospital, Mianyang, Sichuan, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hwa Mei Hospital, University of Chinese Academy of Sciences, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.